ADJUVANT SYSTEMIC THERAPY FOR OPERABLE BREAST-CANCER

被引：2
|
作者：
STEWART, HJ
机构：
[1] The Scottish Cancer Trials Office (MRC), Medical School, University of Edinburgh, Edinburgh
来源：
BRITISH MEDICAL BULLETIN | 1991年 / 47卷 / 02期
关键词：
D O I：
10.1093/oxfordjournals.bmb.a072475
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Adjuvant systemic therapy is now an important and recognized part of the initial management of patients with operable breast cancer. Its value in delaying relapse and prolonging total survival is established for disease of poor prognosis. For premenopausal patients the currently advised treatment is a 6 month course of CMF polychemotherapy and for postmenopausal patients it is daily tamoxifen for 2-5 years. For patients with disease of good prognosis there is a need to evaluate, within randomized trials, the usefulness of newer biological indicators of prognosis to improve selection for and of treatment. Continued monitoring of long-term results for delayed morbidity is also necessary.
引用
收藏
页码：343 / 356
页数：14
相关论文
共 50 条
  • [31] ADJUVANT SYSTEMIC THERAPY IN BREAST-CANCER .2. ADJUVANT CHEMOTHERAPY
    TIVER, KW
    BOYAGES, J
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1992, 62 (06): : 450 - 462
  • [32] Neoadjuvant therapy for operable breast-cancer
    Insa, A
    Chirivella, I
    Lluch, A
    [J]. MEDICINA CLINICA, 2006, 126 (08): : 295 - 303
  • [33] ADJUVANT SYSTEMIC THERAPY IN BREAST-CANCER .1. ADJUVANT HORMONE-THERAPY
    BOYAGES, J
    TIVER, KW
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1992, 62 (05): : 354 - 363
  • [34] ADJUVANT STUDY WITH COMBINATION CHEMOTHERAPY IN OPERABLE BREAST-CANCER
    BONADON, G
    BRUSAMOLINO, E
    VALAGUSSA, P
    VERONE, U
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1975, 16 (MAR): : 254 - 254
  • [35] ADJUVANT CHEMOIMMUNOTHERAPY OF OPERABLE BREAST-CANCER - UPDATED REPORT
    BUZDAR, AU
    BLUMENSCHEIN, GR
    TASHIMA, CK
    GUTTERMAN, JU
    HORTOBAGYI, GN
    YAP, HY
    CAMPOS, LT
    SMITH, TL
    HERSH, EM
    FREIREICH, EJ
    GEHAN, EA
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 334 - 334
  • [36] ADJUVANT CHEMOTHERAPY FOR OPERABLE BREAST-CANCER IN PREMENOPAUSAL WOMEN
    FALKSON, HC
    FALKSON, G
    PORTUGAL, MA
    SCHOEMAN, HS
    [J]. SOUTH AFRICAN MEDICAL JOURNAL, 1982, 61 (18): : 651 - 655
  • [37] ADJUVANT HORMONO-CHEMOTHERAPY IN OPERABLE BREAST-CANCER
    WILSON, R
    HANHAM, IWF
    MAIR, G
    DRAKE, SR
    DERRY, CD
    MCKENZIE, C
    STOLL, BA
    BOESEN, E
    SKEGGS, DBL
    SENANAYAKE, F
    [J]. LANCET, 1978, 1 (8073): : 1101 - 1101
  • [38] ADJUVANT CHEMOTHERAPY IN PRIMARY TREATMENT OF OPERABLE BREAST-CANCER
    THOMDELSEN, K
    TRAMS, G
    [J]. ARCHIV FUR GYNAKOLOGIE, 1977, 224 (1-4): : 361 - 362
  • [39] PERIOPERATIVE BROMOCRIPTINE ADJUVANT TREATMENT FOR OPERABLE BREAST-CANCER
    FENTIMAN, IS
    BRAME, K
    CHAUDARY, MA
    CAMPLEJOHN, RS
    WANG, DY
    MILLIS, RR
    [J]. LANCET, 1988, 1 (8586): : 609 - 610
  • [40] COMBINATION CHEMOTHERAPY AS AN ADJUVANT TREATMENT IN OPERABLE BREAST-CANCER
    BONADONNA, G
    BRUSAMOLINO, E
    VALAGUSSA, P
    ROSSI, A
    BRUGNATELLI, L
    BRAMBILLA, C
    DELENA, M
    TANCINI, G
    BAJETTA, E
    MUSUMECI, R
    VERONESI, U
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (08): : 405 - 410
12345